MannKind | MNKD - Należności Handlowe





Należności Handlowe Zmiana Data
Adma Biologics USD 158.43M 20.76M 2025-12
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Eli Lilly USD 19.46B 2.25B 2025-09
Halozyme Therapeutics USD 441.27M 95.24M 2025-12
Insmed USD 140.86M 75.6M 2025-12
Karyopharm Therapeutics USD 26.18M 5.6M 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
MannKind USD 38.37M 20.98M 2025-12
Merck USD 12.12B 596M 2025-09
Novavax USD 106.45M 72.27M 2025-12
Novo Nordisk DKK 14.27B 72.1B 2025-06
Pfizer USD 18.12B 2.02B 2025-09
Sanofi EUR 482M 85M 2026-03
Xencor USD 29.3M 7.49M 2025-12